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Abstract
The present study describes the degradation of tenoforvir disoproxil fumarate (teno) under different prescribed stress
conditions (hydrolysis, oxidation, dry and wet heat and photolysis) following the International Conference on Harmoniza-
tion and application of a specific and selective stability-indicating reversed-phase high–performance liquid chromatography
(HPLC) assay. Separation of drug and degradation products was successfully achieved on C18 analytical column using
methanol: water (60:40, v/v) at a flow rate of 1.0 ml/min and detection at 260 nm, the mass balance was found to be close to
100.4%. The developed HPLC method was validated with respect to linearity, accuracy, precision, robustness, and accuracy.
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1. Introduction
Tenofovir is intracellularly converted to diphosphate.
This diphosphate halts the DNA synthesis of HIV through
competitive inhibition of reverse transcriptase and incorpora-
tion into viral DNA. It also inhibits hepatitis B virus poly-
merase, resulting in inhibition of viral replication. It is used
in  the  treatment  of  HIV  infection  and  chronic  hepatitis  B
infection.  Tenofovir  disoproxil  fumarate  (short:  teno)  is  a
fumaric  acid  salt  of  the  bisisopropoxycarbonyloxymethyl
ester derivative of tenofovir. Chemically it is 9-[(R)-2-[[(iso-
propoxcarbonyl)-oxy]methoxy]phosphiny] methoxy]propyl]
adeninefumarate (Figure 1). It is not official in any of the
pharmacopoeias.  This  is  listed  in  the  Merck  Index  and
Martindale: The complete drug reference can be found at a
Budawari, et al. (2001) and Sweetman, et al. (2005).
Literature review reveals that several methods have
been reported for the estimation of teno in tablets (Patel et
al., 2009; Raju and Begum et al., 2009; Karunakaran et al.,
2010; Behera et al., 2011), using high-performance liquid
chromatographic  (HPLC)  methods  (Jullien  et  al.,  2003;
Sentenac  et  al.,  2003;  Rezk  et  al.,  2005;  Kandagal  et  al.,
2008; Seshachalam et al., 2008), LC-MS (Bezy et al., 2005;
Delahunty et al., 2006; King et al., 2006; Barkil et al., 2007;
Massaki  et  al.,  2007;  Delahunty  et  al.,  2009),  and  high-
performance  thin  layer  liquid  chromatographic  methods
(Joshi, et al. 2006).
HPLC is a versatile technique, and HPLC with UV de-
tection is often preferred in ordinary laboratories and quality
controlled  laboratories  because  of  its  wide  suitability  and
availability. So far, to our present knowledge, no stability-
indicating LC assay method for the determination of teno is
available in the literature. It was felt necessary to develop a
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stability indicating LC method for the determination of teno
as bulk drug and pharmaceutical dosage form and separate
the  drugs  from  the  degradation  products  under  the  ICH
(International  Conference  on  Harmonization)  suggested
conditions.
The  aim  of  the  present  study  was  to  establish  the
inherent stability of tenofovir disoproxil fumarate through
stress studies under a variety of ICH recommended test con-
ditions (International Conference on Harmonization, 1996;
Singh and Bakshi et al., 2000; International Conference on
Harmonization, 2003) and to develop a stability-indicating
assay (Carstensen et al., 2000; Singh and Bakshi et al., 2002;
Singh et al., 2006).
2. Experimental
2.1 Chemical and reagents
Pharmaceutical  grade  teno  working  standard  was
obtained as generous gifts from Ranbaxy Pvt. Ltd. Indore,
India. Commercially available Tentide tablets (300 mg) [T-I]
were purchased from Ranbaxy Pvt. Ltd. India and Tavin (300
mg) [T-II] from Emcure pharmaceuticals. All chemicals and
reagents  were  of  HPLC  grade  and  were  purchased  from
Merck Chemicals, Mumbai, India.
2.2 Instrumentation
2.2.1  Stress study
High  precision  heating  mantel  (Narang  Scientific
Works, New Delhi, India) capable of controlling the tempera-
ture with in ±1°C was used for generating hydrolytic degrad-
ation products. The thermal degradation study was performed
using a high precision hot air oven (Kumar Scientific Works,
Pune, India) capable of controlling the temperature with in
±2°C. Photo-degradation was carried out in a photostability
chamber (Thermolab, Scientific Equipment Pvt Ltd.) equipped
with lighting system to comply with ICH guideline for photo-
stability condition with white fluorescent light exposure for
1.2 milion lux hours and integrated near ultra violet energy
exposure  of  200  watts  hours/sq  mts  (Option  2  of  the  ICH
guideline  Q1B).  At  any  given  time,  UV  energy  and  visible
illumination were tested using a calibrated lux meter (Lutron,
LX-101A).
2.2.2  LC–UV analyses
The LC system consisted of a pump (model Jasco
PU1580, intelligent LC pump) with auto injecting facility (AS-
1555 sampler) programmed at 20 µl capacity per injection.
The detector consisted of a UV–vis (Jasco UV 1575) model
operated at a wavelength of 260 nm (Figure 2). The software
used was Jasco borwin version 1.5, LC-Net II/ADC system.
The column used was HiQ Sil C18HS (250 mm×4.6 mm, 5.0
µm) Kya Technologies Corporation, Japan.
2.3 Preparation of standard stock solutions
Standard  stock  solutions  of  teno  was  prepared  in
acetonitrile  of  concentration  1  mg/ml.  Working  standard
solutions were prepared by serial dilution of the stock solu-
tion with the mobile phase.
2.4 General assay procedure
2.4.1  Preparation of the calibration graph
Working standard solutions containing 4.0–20.0 µg/
ml of teno were prepared by serial dilution of aliquots of the
stock solution and triplicate injections were made of each
solution and the peak areas of teno were plotted against the
corresponding concentration (µg/ml) to obtain the calibra-
tion  graph.  The  corresponding  regression  equation  was
derived.
2.4.2  Analysis of bulk substance
The method mentioned above was applied for the
determination of the purity of teno raw material. The percent-
age recoveries were calculated by referring to the calibration
graph previously prepared or applying the regression equa-
tion.
2.4.3  Procedure for stress testing
A  stock  solution  containing  100  mg  teno  in  100  ml
acetonitrile was prepared. This solution was used for forced
degradation to provide an indication of the stability-indicat-
ing ability and specificity of the proposed method. In all de-
gradation studies, the average peak area of teno (10 µg/ml)
after application of six replicates was obtained.
Hydrolysis: 5 ml of a standard stock solution (1 mg/
ml) was mixed with 5 ml 0.01 M HCl at room temperature.
The alkaline hydrolysis was carried out by mixing a standard
stock solution 5 ml (1 mg/ml) with 0.01 M NaOH (5 ml) kept
at room temperature. The solution was then neutralized with
0.01M NaOH and 0.01 M HCl for the acidic and alkaline de-
gradation, respectively
Oxidation:  For  the  purpose  of  oxidation  studies  a
mixture of 5 ml standard stock solution and 5 ml hydrogen
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peroxide (0.3%, v/v) was kept at room temperature and then
heated  in  a  boiling  water  bath  for  10  min  to  completely
remove the excess hydrogen peroxide.
Dry heat degradation: 10 mg standard drug as powder
was placed in an oven at 50°C for two months to study the
dry heat degradation.
Photochemical degradation: Photo degradation stud-
ies were carried out according to Option 2 of Q1B in the ICH
guidelines. The stock solution (1 mg/ml) as well as the solid
drug was exposed to light for an overall illumination of 1.2
million lux/hr and an integrated near ultraviolet energy of
200 W hm
-2 for 8 hrs.
Neutral hydrolysis: To study the degradation behav-
ior of drug in neutral conditions, 5 ml of a standard stock
solution (1 mg/ml) was mixed with 5 ml double distilled water
and heated at 80°C for 5 days, and subsequently for 10 days.
2.4.4  Analysis of dosage forms
For the analysis of tablets, 20 tablets of each batch
T-I and T-II were weighed and finely ground in a mortar. For
T-I and T-II, the portion equivalent to 300 mg of teno was
transferred in a 50 ml volumetric flask, 35 ml of acetonitrile
was then added, and sonication was done for 45 min with
swirling. After sonication, the volume was made up to the
mark with the acetonitrile and mixed well. The solution was
filtered through Whatman filter paper 41. For both T-I and
T-II, six determinations were performed.
2.5 Optimization of the stability-indicating LC method
The LC procedure was optimized with the objective
of developing a stability indicating assay. After performing
photo degradation of the drug, dilutions were injected and
chromatographed  with  different  mobile  phases.  Initially
mobile phases containing various proportions of methanol:
water were tested. Resolution of the drug peak was good but
peaks of the degradation products were not resolved satis-
factorily. To improve the resolution of the peaks of the de-
gradation products methanol: water (60:40, v/v) was evalu-
ated as mobile phase which enabled good resolution of the
drug from its degradation products. This mobile phase was
used at a flow rate of 1.0 ml/min and detection at 260 nm gave
acceptable retention time (tR), theoretical plate number, and
resolution of the drug and its degradation products
2.6 Analytical method validation
The developed chromatographic method was vali-
dated for linearity, precision, accuracy, sensitivity, robustness
and system suitability.
2.6.1  Linearity and range
Linearity of the method was studied by injecting the
drug solution prepared in the mobile phase in the concentra-
tion range of 4–20 µg/ml, injected six times into the LC system
keeping the injection volume constant. The peak areas were
plotted against the corresponding concentrations to obtain
the calibration graphs.
2.6.2  Precision
Precision of the method was evaluated by analysis of
three independent sample preparations. The determination
of RSD (%) value obtained from three assay values. These
studies were repeated on three different days to determine
inter-day variation. Precision studies were carried at a drug
concentration level of 4, 12, and 20 µg/ml.
2.6.3  Sensitivity
Sensitivity was determined by establishing the limit of
detection (LOD) and limit of quantitation (LOQ). LOD and
LOQ were calculated as 3.3 and 10 ó/S, respectively.
2.6.4  Robustness and system suitability
The robustness was studied by evaluating the effect
of  small  but  deliberate  variations  in  the  chromatographic
conditions. The conditions studied were flow rate (altered
by ±0.1 ml/min), mobile phase composition (methanol ±5
ml).These chromatographic variations were evaluated for
resolution between teno and photo degradation products.
2.6.5  System suitability criteria
The system suitability was assessed by five replicate
analyses of the drugs at a concentration of 4 µg/ml of teno.
2.6.6  Specificity
The specificity of the LC method was determined by
the complete separation of teno in presence of its degrada-
tion products along with other parameters like retention time,
capacity  factor,  tailing,  asymmetrical  factor,  and  others.
Injections of the extracted placebo were performed to de-
monstrate the absence of interference with the elution of the
teno and degradation products. For determining selectivity
of the method, a powder blend of typical tablet excipients
containing  lactose  monohydrate,  mannitol,  maize  starch,
povidone K30, citric acid anhydrous granular, sodium citrate,
natural lemon and lime flavour, acesulfame potassium and
magnesium stearate was prepared and analyzed. All chro-
matograms  were  examined  to  determine  if  compounds  of
interest co-eluted with each other or with any additional ex-
cipients peaks.
2.6.7  Accuracy
Accuracy of the method was tested by applying the
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standard  powder  corresponding  to  80,  100,  and  120%  of
label  claim  had  been  added  (standard  addition  method),
mixed  and  the  powder  was  extracted  and  analyzed  by
running chromatograms in optimized mobile phase. These
mixtures were analyzed by the proposed method. The experi-
ment was performed in triplicate and recovery (%) was calcu-
lated.
2.6.8  Analysis of marketed formulation
The contents of drug in tablets were determined by
the proposed method using the calibration curve.
2.6.9  Solution stability and mobile phase stability
The solution stability of teno was carried out by leav-
ing the test solution in tightly capped volumetric flasks at
room temperature for 24 hrs and assayed at 6 hrs interval,
against the freshly prepared standard solution. The mobile
phase  stability  was  carried  out  by  assaying  the  freshly
prepared standard solution at 24 hrs interval up to 48 hrs. The
%RSD of assay of teno was calculated for the study period
during mobile phase and solution stability experiments.
3. Results and Discussion
3.1 Method development and optimization
Initially, mobile phases containing various propor-
tions of methanol:water were tested. Sufficient separation
between drug and degradation products was observed using
methanol:water (60:40, v/v) gave acceptable retention time
(tR 12.09 min) (Figure 3).
3.2 Detection of degradation products by HPLC
3.2.1  Hydrolysis
Acid and alkaline degradation of teno was performed
in 1:1 acetonitrile–0.01 M HCl and NaOH. teno was highly
susceptible to attack by HCl and NaOH. Complete degrada-
tion occurred immediately after addition of HCl and NaOH
at room temperature.
3.2.2  Oxidation
The drug was found to be unstable to oxidative degra-
dation. In 1:1 acetonitrile– 0.3% H2O2 complete degradation
occurs immediately at room temperature.
3.2.3  Dry and wet heat degradation product
There was no significant degradation of solid teno on
exposure to dry heat at 50°C for two months, which indicated
that drug was stable against thermal stress.
3.2.4  Photolysis
Teno  was  degraded  in  photochemical  degradation
after exposing drug to a combination of white fluorescent
and integrated near ultra violet energy at 1.2 million lux/hr
and 200 watts hours/sq mts, respectively for 8 hrs forming
three  major  degradation  products  at  1.14  and  2.01  min
(Figure 4).
3.2.5  Neutral degradation
Teno under neutral hydrolysis did not give rise to the
presence of degradants as the peak area remained constant
which indicated drug stability under the conditions investi-
gated.
Figure 3. Chromatogram of tenoforvir disoproxil fumarate (20 mg/
ml), tR : 12.01 min; measured at 260 nm, mobile phase:
methanol:water (60:40 v/v).
Figure 4. Chromatogram of photo degradation of tenofovir (10 µg/
ml); peak 1 (degraded) (tR: 1.14 min), peak 2 (degraded)
(tR: 2.01 min), peak 3 (tenofovir disoproxil fumarate) (tR:
12.16 min).619 S. Havele & S. R. Dhaneshwar / Songklanakarin J. Sci. Technol. 34 (6), 615-622, 2012
3.3 Validation
3.3.1  Linearity
Good  linearity  was  observed  in  the  concentration
range of 4–20 µg/ml of teno (Figure 5). The data was subjected
to statistical analysis using a linear regression model; the
result shows that within the concentration range mentioned
above, there was an excellent correlation between peak area
and concentration of each drug (Table 1).
3.3.2  Precision
The developed method was found to be precise, with
%RSD values for repeatability 0.09% and 0.46% for interday
precision, as recommended by ICH guidelines.
3.3.3  LOD and LOQ
The LOD and LOQ values were found to be 0.01 and
0.03 µg/ml.
3.3.4  Specificity
Injections of the extracted placebo were performed to
demonstrate the absence of interference with the elution of
the drugs. These results demonstrate that there was no inter-
ference from other materials in the tablet formulation; there-
fore, confirm the specificity of the method (Figure 6).
3.3.5  System suitability
System suitability parameters such as the number of
theoretical plates, HETP and peak tailing were determined.
The results obtained are shown in Table 2.
3.3.6  Robustness of the method
Each factor selected was changed at three levels (-1, 0,
and 1). One factor at a time was changed to determine the
effect. Thus, replicate injections (n=6) of mixed standard
solution at three concentration levels were performed under
small changes of three chromatographic parameters (factors).
Insignificant variability in retention time, capacity factor and
U.S.P. tailing factor were observed (Table 3).
Table 1. Linear regression data for the calibration curves
a.
y = A + Bx
Compound r
2
A B
teno 4-20 104.2 4717 0.9999
a n = 6;  r
2, coefficient of correlation
Linearity
(µg/ml)
Table 2. Statistical  analysis  of  parameters  required  for
system  suitability  testing  of  the  proposed  HPLC
method (n = 3 determinations).
Parameters Teno
N 5156.2120
tR 12.16
T 1.0374
% R.S.D. 0.04
Figure 5.  Calibration curve for tenofovir.
Figure 6.  Representative chromatogram obtained for the placebo.
Table 3. Robustness testing
a.
Chromatographic Factors
 a Level tR
b k
c T
d
Flow rate (ml/min) 0.9 12.74 2.26 1.18
1.0 12.16 2.28 1.03
1.2 12.02 2.43 1.00
% of methanol (v/v) 55 12.98 2.45 1.29
60 12.16 2.28 1.03
65 12.03 1.22 1.01
a  n = 6, tR = Retention time in minutes; T = USP tailing factor,
k
c = capacity factorS. Havele & S. R. Dhaneshwar / Songklanakarin J. Sci. Technol. 34 (6), 615-622, 2012 620
3.3.7  Solution and mobile phase stability studies
No additional peak was found in the chromatogram.
The results from solution stability and mobile phase stability
experiments confirmed that standard solutions and solutions
in the mobile phase were stable up to 48 hrs for assay and
related substances analysis.
3.3.8  Recovery studies
Good recoveries of the teno were obtained at various
added concentrations for T-I and T-II as shown in Table 4.
3.3.9  Analysis of a commercial formulation
Experimental results of the amount of teno in tablets,
expressed as a percentage of label claims were in good agree-
ment with the label claims thereby suggesting that there is no
interference from any of the excipients, which are normally
present in tablets. Two different brands of fixed dose combi-
nation tablets were analyzed using the proposed procedures
(Table 5).
Finally, a summary of the validation parameters are
listed in Table 6 and of the stress study in Table 7.
Table 4. Recovery studies
a.
Label claim Amount of Total amount of Amount found % Recovery
drug added (%) drug present (µg/ml) (µg/ml)
T-I
   300 mg 80 10.8 10.76 99.62
100 12 11.92 99.33
120 13.2 13.13 99.46
T-II
   300 mg 80 10.8 10.71 99.16
100 12 11.96 99.66
120 13.2 13.17 99.77
a n = 6
Table 5. Applicability of the HPLC method for the analysis
of the pharmaceutical formulations.
Label claim (mg) Sample Drug Content (%) % R.S.D.
300 T-I 99.90 0.07
T-II 100.35 0.10
Table 6. Summary of validation parameters.
               Parameter Teno
Linearity range (µg/ml) 4-120
Correlation coefficient 0.999±0.81
Limit of detection (µg/ml) 0.01
Limit of quantitation (µg/ml) 0.03
Recovery (n=6)
   T-I 99.47
   T-II 99.53
Precision (% R.S.D.)
   Repeatability 0.09
   Inter day 0.46
Robustness Robust
Specificity Specific
Table 7. Summary of the stress study.
           Condition Time Assay of active Mass balance (% assay + Degradation tR of major degradation
(hrs) substance % sum of impurities + (%) product (min)
(%) sum of all degradents)
Exposed to a combina- 8 91.93 100.29 5.96, 1.96 1.14, 2.01
tion of white fluorescent
and integrated near
ultra violet energy at
1.2 mil lux hours and
200 watts hours/sq mts,
respectively621 S. Havele & S. R. Dhaneshwar / Songklanakarin J. Sci. Technol. 34 (6), 615-622, 2012
4. Conclusion
This study showed that tenofovir disoproxil fumarate
was found to be unstable under acidic, alkaline and oxidative
conditions as it degraded completely, but it was found that
it  is  labile  to  photolysis  and  that  complete  separation  of
degradants was carried out using an isocratic stability-indi-
cating  HPLC  method.  Tenofovir  disoproxil  fumarate  was
observed to be stable when exposed to neutral condition, wet
and dry heat. The developed HPLC method proved to be
simple, accurate, precise and specific. Hence, it is recom-
mended  for  industrial  analysis  of  drug  and  degradation
products obtained from stability procedures.
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